As SQZ faced a final reckoning, a fateful board decision steered the company to a quick and brutal endgame
A decade after SQZ was birthed amid considerable enthusiasm and midwifed by one of the biggest scientific stars in Cambridge, MA, the few survivors of its collapse are waving a white flag of surrender.
On Tuesday, investors got word that Roche had formally bowed out of its alliance with SQZ on the lead program, leaving the dwindling team — led by execs handed retainer bonuses a month ago — to work on any kind of deals they could find. That’s a common sight these days in biotech, as the sorting of survivors and burials continues to offer some final accounting of once-grand ambitions.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.
